PSC
TECH icon

Piper Sandler & Co’s Bio-Techne TECH Stock Holding History

Piper Sandler & Co’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,000
Closed -$254K – 145
2014
Q4 		$254K Buy
+11,000
New +$252K 0.12% 74

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's TECH Position: Q1 2015 in Review

Piper Sandler & Co sold out of Bio-Techne (TECH) in Q1 2015, closing a stake of 11,000 shares — an estimated $254K sold.

Piper Sandler & Co first reported a position in TECH in Q4 2014 and held it in 1 quarter. The position peaked at $254K in Q4 2014. 252 funds tracked by Wall St. Rank hold TECH as of Q1 2015.

  • Piper Sandler & Co reported no remaining Bio-Techne position as of Q1 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 11,000 Bio-Techne shares in Q1 2015, an estimated $254K.
  • Piper Sandler & Co first reported a position in Bio-Techne in Q4 2014 and held it in 1 quarter.
  • Piper Sandler & Co's Bio-Techne position peaked at $254K in Q4 2014.
  • 252 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2015.

Based on Piper Sandler & Co's 13F filing for Q1 2015, filed 15 May 2015.